The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Press Releases Subscribe to our News

30. November 2022

Regulatory

Biosergen publishes interim report for third quarter 2022

Release
Q3-2022 Financial Report
20. Oktober 2022

Non-Regulatory

Biosergen’s warrants of series TO2 are admitted to trading

Release
19. Oktober 2022

Non-Regulatory

Biosergen allocates shares to an underwriter in connection with the completed rights issue

Release
05. Oktober 2022

Non-Regulatory

Biosergen appoints Mangold Fondkommission to act as a liquidity provider

Release
04. Oktober 2022

Regulatory

Biosergen announces the outcome in the rights issue

Release
26. September 2022

Non-Regulatory

Mangold Insight publishes interview with Biosergen’s CEO

Release
15. September 2022

Non-Regulatory

The subscription period in Biosergen’s rights issue starts today

14. September 2022

Non-Regulatory

Biosergen AB: Correction regarding ISIN code for unit rights in rights issue

Release
13. September 2022

Non-Regulatory

Biosergen AB: Biosergen publishes prospectus due to rights issue of units

Release
EU-tillväxtprospekt - Biosergen
08. September 2022

Regulatory

Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.

Release
02. September 2022

Regulatory

Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million

Release
31. August 2022

Regulatory

Biosergen publishes interim report for second quarter 2022

Release
Q2-2022 Financial Report

Regulatory

Biosergen receives a loan of SEK 7 million to finance continued development

Release
26. August 2022

Regulatory

Biosergen completes the third cohort of BSG005 phase I trial

Release
11. Juli 2022

Non-Regulatory

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

Release
30. Juni 2022

Regulatory

Biosergen successfully completes second cohort of BSG005 phase I trial

Release
28. Juni 2022

Regulatory

Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB

Release
07. Juni 2022

Regulatory

Biosergen publishes 2021 Annual report

Release
31. Mai 2022

Regulatory

Biosergen publishes interim report for first quarter 2022

Release
2022-Q1 Financial Report
25. Mai 2022

Non-Regulatory

NOTICE OF ANNUAL GENERAL MEETING IN BIOSERGEN AB

Release

Non-Regulatory

KALLELSE TILL ÅRSSTÄMMA I BIOSERGEN AB

Release
13. Mai 2022

Regulatory

Biosergen successfully completes first cohort of BSG005 phase I trial

Release
02. Mai 2022

Non-Regulatory

Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.

Release
19. April 2022

Non-Regulatory

The first subjects dosed successfully with no adverse events in the phase I trial of BSG005

Release
07. April 2022

Regulatory

The first subject has been dosed in the phase I trial of BSG005

Release
31. März 2022

Regulatory

Biosergen publishes interim report for fourth quarter 2021

Biosergen Q4 financial report press release
Q4-2021 Financial Report
30. November 2021

Regulatory

Biosergen publishes interim report for the third quarter 2021

Q3-2021 Financial Report
Biosergen Q3 financial report press release
31. August 2021

Regulatory

Biosergen publishes interim report for the second quarter 2021

Q2-2021 Financial Report
Biosergen Q2 report press release
24. August 2021

Non-Regulatory

Biosergen’s application to start human clinical trials with BSG005 is approved

Release
19. August 2021

Non-Regulatory

Tine Kold Olesen will join Biosergen AB as Chief Operating Officer

Release
27. Juni 2021

Regulatory

Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States

Release
23. Juni 2021

Non-Regulatory

BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.

Biosergen listing approval
08. Juni 2021

Regulatory

BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED

Biosergens offering fully subscribed
31. Mai 2021

Non-Regulatory

The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity

Release
19. Mai 2021

Non-Regulatory

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)

Non-Regulatory

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)